New method to give Diamyd® will be tested in adults with type 1 diabetes

Diamyd Medical (NASDAQ OMX First North, Ticker: DMYD B) informs that a new way to give Diamyd® will be tested in a clinical study with five adults newly diagnosed with type 1 diabetes. The investigator initiated study has been approved by the Swedish MPA.In analogy to the development in allergy therapy, where the administration of allergen into lymph nodes has significantly improved the efficacy, Diamyd® will in this study be administered directly into lymph nodes in combination with treatment with vitamin D. “This is an innovative approach that may become important both for the